GlassScriptPhysician profile
Laura Grogan Wilson
NPI 1548014301
$1,799.88
in general payments reported to CMS, 2019-2025
28 companies · $738 in 2025
The $738 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,062 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,799.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $326.63 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $268.45 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $233.85 | 2024-2025 | |
| Lilly USA, LLC | $145.18 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $127.27 | 2024-2025 | |
| Axsome Therapeutics, INC. | $82.44 | 2024 | Auvelity |
| Amneal Pharmaceuticals LLC | $74.84 | 2024-2025 | Unithroid, Crexont |
| Exact Sciences Corporation | $44.04 | 2024-2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $42.07 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.20 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.15 | 2024-2025 | Jardiance |
| Seqirus USA INC | $38.17 | 2025 | Flucelvax, Fluad |
| Glaxosmithkline, LLC. | $29.36 | 2025 | Arexvy, Trelegy Ellipta |
| Tandem Diabetes Care, INC. | $28.11 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $27.70 | 2025 | Inceptiv |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $27.65 | 2024 | Impella |
| Organon LLC | $25.85 | 2024-2025 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $23.91 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $22.61 | 2024 | Rexulti |
| Boston Scientific Corporation | $19.29 | 2024 | Wavewriter Alpha Prime 16 |
| Renalytix Ai, INC. | $18.49 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Astellas Pharma US INC | $18.21 | 2024 | Veozah |
| Neos Therapeutics, LP | $17.75 | 2024 | Adzenys Xr-Odt |
| Corcept Therapeutics | $16.73 | 2024 | Korlym |
| Merck Sharp & Dohme LLC | $15.78 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Tris Pharma INC | $15.36 | 2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $14.51 | 2024 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.28 | 2025 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.